Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy

Lancet

Volumn 355, Issue 9200, 2000, Pages 253-259

  Gerstein, H C ^a   Yusuf, S ^a   Mann, J F E ^a   Hoogwerf, B ^a   Zinman, B ^a   Held, C ^a   Fisher, M ^a   Wolffenbuttel, B ^a   Bosch, J ^a   Richardson, L ^a   Pogue, J ^a   Halle, J P ^a  

^a HGH McMaster Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0034700790     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)12323-7     Document Type: Article

References (34)

1. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
2. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham study. JAMA. 241:1979;2035-2038.
3. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ. 287:1983;867-870.
4. Barrett-Connor E., Cohn B.A., Wingard D.L., Edelstein S.L. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 265:1991;627-631.
5. Goldbourt U., Yaari S., Medalie J.H. Factors predictive of long-term coronary heart disease mortality among 10059 male Israeli civil servants and municipal employees: a 23 year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 82:1993;100-121.
6. Manson J.E., Coldlitz G.A., Stampfer M.J.et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 151:1991;1141-1147.
7. Wingard D.L., Barrett-Connor E. Heart disease and diabetes. Harris M.I., Cowie C.C., Stern M.S., Boyko E.J., Reiber G.E., Bennett P.H. Diabetes in America, 2nd edn. 1995;429-448 National Institutes of Health, Washington.
8. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 48:1999;937-942.
9. Morrish N.J., Stevens L.K., Fuller J.H., Keen H., Jarrett R.J. Incidence of macrovascular disease in diabetes mellitus: the London follow-up to the WHO multinational study of vascular disease in diabetics. Diabetologia. 34:1991;584-589.
10. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment of diabetic retinopathy study report 14. JAMA. 266:1992;1292-1300.
11. Damsgaard E.M., Froland A., Jorgensen O.D., Mogensen C.E. Eight to nine year mortality in known non-insulin dependent diabetes and controls. Kidney Int. 42:1992;731-735.
12. Neil A., Hawkins M., Potok M., Thorogood M., Cohen D.A., Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 16:1993;996-1003.
13. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA. 281:1999;1291-1297.
14. Zuanetti G., Latini R., Maggioni A.P., Franzosi M., Santoro L., Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 96:1997;4239-4245.
15. Hansson L., Lindholm L.H., Niskanen L.et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353:1999;611-616.
16. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 317:1998;703-713.
17. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 317:1998;713-720.
18. Tatti P., Pahor M., Byington R.P.et al. Outcome results of the Fosinopril versus Amlodipiine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 21:1998;597-603.
19. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 338:1998;645-652.
20. Shindler D.M., Kostis J.B., Yusuf S.et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 77:1996;1017-1020.
21. Chaturvedi N., Sjolie A.K., Stephenson J.M.et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 351:1998;28-31.
22. Gerstein H.C., Bosch J., Pogue J.et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabetes Care. 19:1996;1225-1228.
23. The HOPE (Heart Outcomes Prevention Evaluations) Study: the design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 12:1996;127-137.
24. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;. (in press).
25. Yusuf S., Lonn E. Anti-ischemic effects of ACE inhibitors: a review of current clinical evidence and ongoing clinical trials. Eur Heart J. 19:1998;J36-44.
26. Curb J.D., Pressel S.L., Cutler J.A.et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 276:1996;1886-1892.
27. Lonn E.M., Yusuf S., Jha P.et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
28. Hansson L., Lindholm L.H., Ekbom T.et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 354:1999;1751-1756.
29. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study. Arch Intern Med. 156:1996;286-289.
30. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 118:1993;577-581.
31. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
32. Parving H.H., Gall M.A., Skott P.et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 41:1992;758-762.
33. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 341:1999;1127-1133.
34. Olsen S., Mogensen C.E. How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia. 39:1996;1638-1645.